Skip to main content
main-content

08.09.2016 | Gastrointestinal Oncology | Sonderheft 5/2016

Annals of Surgical Oncology 5/2016

Quality-of-Life Evaluation After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy

Zeitschrift:
Annals of Surgical Oncology > Sonderheft 5/2016
Autoren:
MD Rebecca M. Dodson, PhD Richard P. McQuellon, MD Harveshp D. Mogal, PhD Katharine E. Duckworth, MS Gregory B. Russell, MD, PhD Konstantinos I. Votanopoulos, MD Perry Shen, MD Edward A. Levine
Wichtige Hinweise
Presented at the Society of Surgical Oncology 69th Annual Symposium, Boston, MA, March 5, 2016.

Abstract

Background

Cytoreductive surgery (CS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastases can alleviate symptoms and prolong survival at the expense of morbidity and quality of life (QoL). This study aimed to monitor QoL and outcomes before and after HIPEC.

Methods

A prospective QoL trial of patients who underwent HIPEC for peritoneal metastases from 2000 to 2015 was conducted. The patients completed the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36), the Functional Assessment of Cancer Therapy + Colon Subscale (FACT-C), the Brief Pain Inventory, the Center for Epidemiologic Studies Depression scale, and the Eastern Cooperative Oncology Group (ECOG) performance status at baseline, then 3, 6, 12, and 24 months after HIPEC. The trial outcome index (TOI) was analyzed. Proportional hazards modeled the effect of baseline QoL on survival.

Results

The 598 patients (53.8 % female) in the study had a mean age of 53.3 years. The overall 1-year survival rate was 76.8 %, and the median survival period was 2.9 years. The findings showed a minor morbidity rate of 29.3 %, a major morbidity rate of 21.7 %, and a 30-day mortality rate of 3.5 %. The BPI (p < 0.0001) and worst pain (p = 0.004) increased at 3 months but returned to baseline at 6 months. After CS + HIPEC, FACT-C emotional well-being, SF-36 mental component score, and emotional health improved (all p < 0.001). Higher baseline FACT-General (hazard ratio [HR], 0.92; 95 % confidence interval [CI], 0.09–0.96), FACT-C (HR, 0.73; 95 % CI 0.65–0.83), physical well-being (HR, 0.71; 95 % CI 0.64–0.78), TOI (HR, 0.87; 95 % CI 0.84–0.91), and SF-36 vitality (HR, 0.88; 95 % CI 0.83–0.92) were associated with improved survival (all p < 0.001). Higher baseline BPI (HR, 1.1; 95 % CI 1.05–1.14; p < 0.0001), worst pain (HR, 1.06; 95 % CI 1.01–1.10; p = 0.01), and ECOG (HR, 1.74; 95 % CI 1.50–2.01; p < 0.0001) were associated with worse survival.

Conclusions

Although HIPEC is associated with morbidity and detriments to QoL, recovery with good overall QoL typically occurs at or before 6 months. Baseline QoL is associated with morbidity, mortality, and survival after HIPEC.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel

Weitere Artikel der Sonderheft 5/2016

Annals of Surgical Oncology 5/2016 Zur Ausgabe
  1. Sie können e.Med Chirurgie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Chirurgie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Chirurgie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise